DCTH.US Delcath Systems Inc

Healthcare Health Care Equipment & Supplies USA Stocks
20.55 USD
Close of Nov 14, 2026
8.12 22.51
Market cap
USD 715M
P/E
128.4x
P/B
5.56x
ROE
8.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DCTH.US undervalued?

Graham number

The Graham number of Delcath Systems Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Delcath Systems Inc fundamental analysis

No fundamental analysis for Delcath Systems Inc yet.

Delcath Systems Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Delcath Systems Inc

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic he…

Full company profile